NCT06087198已完成不适用
Clinical Performance Evaluation of T-TAS®01 HD Chip
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 6
- 主要终点
- Improvement in thrombogenicity
研究概览
简要总结
The study is being conducted to validate the clinical performance of the T-TAS 01 HD assay for measurement of thrombogenicity in patients with thrombocytopenia receiving a platelet transfusion.
详细描述
This study will measure the improvement in thrombogenicity following platelet transfusion in patients with thrombocytopenia, using the T-TAS 01 HD assay, with a comparison with clinical truth, defined as the confirmation of increased platelet count attributed to platelet transfusion. The study will be conducted at a minimum of 3 locations in the United States and will enroll up to 90 subjects with thrombocytopenia and 50 healthy control subjects. The following subject populations will be enrolled into the study (enrollment numbers indicated in parentheses):
- Ostensibly healthy subjects with a normal platelet count and without a history of hemostasis abnormalities, for establishing expected values for quality control (N = up to 50)
- Subjects with thrombocytopenia who are planned to receive a platelet transfusion who have pre-transfusion and post-transfusion blood samples collected for testing (N = 50; up to 90 will be enrolled in the event that some subjects do not receive platelet transfusions after enrollment) Subjects will be recruited prospectively, and informed consent will be obtained after confirmation that the enrollment criteria described in Section 5a are satisfied. Blood samples will be collected after enrollment, and subject participation will be complete after all blood samples are collected and all necessary information is collected to complete the case report form (CRF). Blood sample testing with the T-TAS 01 and thromboelastography (TEG) assays will occur locally at each investigational site. Other required laboratory measurements (i.e. CBC) will be performed either locally or remotely, depending on the local availability.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females age 18 years or older.
- •Able and willing to provide written informed consent.
排除标准
- •Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination.
- •Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol.
- •Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.
- •Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 such as rofecoxib, etc. within the past 14 days, unless confirmed to not inhibit platelet activity (such as celecoxib).
- •History of anemia.
- •Known thrombocytopenia (platelet count < 100,000/μL).
- •Significant renal dysfunction (eGFR < 30 mL/min/1.73 m2) or dialysis.
- •History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome.
- •History of hemophilia or bleeding disorders.
- •History of clinically significant bleeding requiring physician consultation or visit to healthcare facility.
- •Females who are in the last trimester of pregnancy or are breastfeeding.
- •Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.
- •Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
- •Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.
- •Thrombocytopenia Patients
- •Inclusion Criteria:
- •Males and females age 18 years or older.
- •Known thrombocytopenia, which may be attributed to any of the following:
- •Immune thrombocytopenia (ITP)
- •Rheumatoid arthritis
- •Aplastic anemia
- •Thrombotic thrombocytopenic purpura (TTP)
- •Disseminated intravascular coagulation (DIC)
- •Heparin induced thrombocytopenia (HIT)
- •Vaccine-induced thrombotic thrombocytopenia (VITT)
- •Infection
- •Other etiologies including trauma, portal hypertension, liver disease, etc.
- •Platelet count < 90,000/μL, confirmed by pre-transfusion CBC
- •Planned platelet transfusion.
- •Able and willing to provide written informed consent
- •Exclusion Criteria:
- •Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, abciximab, eptifibatide within the past 14 days.
- •Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) known to affect platelet function such as rofecoxib, etc. within the past 14 days, unless confirmed to not inhibit platelet activity (such as celecoxib).
- •Surgical procedure on the same day as the baseline blood sample collection and testing
- •Surgical procedure after baseline sample collection and testing, and prior to completion of all post-transfusion blood sample collection and testing
- •Significant renal dysfunction (eGFR < 30 mL/min/1.73 m2) or dialysis.
- •History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann thrombasthenia or Bernard-Soulier syndrome.
- •History of hemophilia or bleeding disorders.
- •Females who are in the last trimester of pregnancy or are breastfeeding.
- •Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.
- •Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
- •Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.
结局指标
主要结局
Improvement in thrombogenicity
时间窗: Day 1 after platelet transfusion
Difference in proportion of T-TAS 01 HD AUC \< 700 between pre-transfusion and post-transfusion measurements
Baseline thrombogenicity
时间窗: Baseline
Proportion of T-TAS 01 HD area under the curve (AUC) \< 700
次要结局
- Comparison of pre-and post-transfusion thrombogenicity(Day 1 after platelet transfusion)
- Correlation with bleeding risk(Day 1 after transfusion)
- Prediction of future platelet transfusions(Day 1 after platelet transfusion)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
Clinical Performance Evaluation of T-TAS 01 PL ChipPlatelet DysfunctionVon Willebrand DiseasesHealthyCongenital Platelets AbnormalityNCT03621020Hikari Dx, Inc.307
终止
2 期
ATX-101 in Advanced Dedifferentiated Liposarcoma and LeiomyosarcomaLeiomyosarcomaLiposarcomaNCT05116683Benjamin Izar4
已完成
不适用
Validation of a New TSH TestSub-clinical HypothyroidismEuthyroidismHypothyroidismNCT01997554Hospices Civils de Lyon1,654
已完成
1 期
Study to Evaluate HT-6184 in Healthy SubjectsNormal Healthy SubjectsNCT05447546Halia Therapeutics, Inc.64
Unknown
不适用
Diagnostic Test for Endometrial Receptivity 24 Hours Before Embryo TransferInfertilityNCT02189369Igenomix120